Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic ...

In a landmark first-in-human study, researchers have harnessed a patient's own fat-derived stem cells—chemically reprogrammed into insulin-producing islets—to restore blood sugar control without daily ...

Q: I have Type 1 diabetes. I try to stay healthy and keep my blood sugar under control, but it feels like a fight every day. I read there's a study using stem cells for a cure. Are there any updates?

Dear Doctors: I have Type 1 diabetes. I try to stay healthy and keep my blood sugar under control, but it feels like a fight every day. I read there’s a study using stem cells for a cure. Are there ...

A small study found that a stem cell-derived treatment helped people with Type 1 diabetes produce their own insulin and, in most cases, enabled patients to discontinue use of external insulin ...

Twelve people with type 1 diabetes who received an investigational off-the-shelf stem cell therapy were able to produce their own insulin and keep healthy blood glucose levels for at least one year, ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) restored insulin production and ended severe hypoglycemia in adults with type 1 ...

In a remarkable medical advancement, Chinese researchers have successfully reversed Type 1 diabetes in a female patient using her stem cells. This significant development could potentially ...

CHICAGO — Ten people with type 1 diabetes, who had recurrent severe hypoglycemia and hypoglycemic unawareness, have remained insulin-independent for over a year following allogeneic stem cell-derived ...

A combination of blood stem cell and pancreatic islet cell transplant from an immunologically mismatched donor completely prevented or cured type 1 diabetes in mice in a study by Stanford Medicine ...

The last time I wrote an article on Sana Biotechnology (SANA) it was with respect to an article entitled "Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus". It is still set to release ...